Original Articles Open access

The association of neutrophil-to-lymphocyte ratio with bronchiectasis severity assessed by the FACED classification in adults with post-tuberculosis bronchiectasis

Authors

Published
27 October 2026
Section
Original Articles

Abstract

The neutrophil-to-lymphocyte ratio (NLR) has emerged as a simple, cost-effective biomarker of systemic inflammation in various respiratory diseases. However, its association with bronchiectasis severity in patients with post-tuberculosis bronchiectasis remains limited. This study aimed to investigate the association between NLR and bronchiectasis severity as assessed by the FACED classification and to identify factors contributing to disease severity in patients with post-tuberculosis bronchiectasis. This retrospective cross-sectional study involved 49 patients with post-tuberculosis bronchiectasis. Bronchiectasis severity was assessed using the FACED score. NLR was calculated from routine complete blood counts. The Mann-Whitney U test compared NLR between mild and moderate severity groups, and factors associated with moderate severity were also analyzed. The median NLR was significantly higher in patients with moderate bronchiectasis compared to those with mild disease (7.16 vs. 3.25, p=0.043), driven primarily by significantly lower lymphocyte percentage in the moderate group (11.20 vs. 22.05, p=0.043). Moderate severity was significantly associated with forced expiratory volume in 1 second <50% predicted (p<0.001), radiological extension involving more than two lobes (p=0.010), and a modified Medical Research Council dyspnea score ≥2 (p=0.049). No significant associations were observed for age, sex, comorbidities, smoking status, or Pseudomonas colonization. Taken together, NLR is significantly elevated in patients with moderate bronchiectasis compared to those with mild disease, primarily reflecting a relatively reduced lymphocyte percentage in more severe disease. As an easily obtainable, inexpensive biomarker, NLR may serve as a practical tool for initial risk stratification in post-tuberculosis bronchiectasis, particularly in resource-limited settings.

Ethics Approval

This study was approved by the Institutional Review Board (IRB) of Persahabatan Hospital (Number 0098/KEPK-RSUPP/03/2026).

References

  1. Chang AB, Fortescue R, Grimwood K, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J 2021;58:2002990. DOI: https://doi.org/10.1183/13993003.02990-2020
  2. Chalmers JD, Mall MA, McShane PJ, et al. A systematic literature review of the clinical and socioeconomic burden of bronchiectasis. Eur Respir Rev 2024;33:240049. DOI: https://doi.org/10.1183/16000617.0049-2024
  3. Chalmers JD, Haworth CS, Flume P, et al. European Respiratory Society clinical practice guideline for the management of adult bronchiectasis. Eur Respir J 2025;66:2501126. DOI: https://doi.org/10.1183/13993003.01126-2025
  4. Martinez-Garcia MA, Guan WJ, de-la-Rosa D, et al. Post-TB bronchiectasis: from pathogenesis to rehabilitation. Int J Tuberc Lung Dis 2023;27:175-81. DOI: https://doi.org/10.5588/ijtld.22.0566
  5. Martínez-García MÁ, de Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014;43:1357-67. DOI: https://doi.org/10.1183/09031936.00026313
  6. Martinez-García MA, Villa C, Dobarganes Y, et al. RIBRON: The spanish Online Bronchiectasis Registry. Characterization of the First 1912 Patients. Arch Bronconeumol 2021;57:28-35. DOI: https://doi.org/10.1016/j.arbr.2020.11.010
  7. Chalmers JD, Polverino E, Crichton ML, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). Lancet Respir Med 2023;11:637-49. DOI: https://doi.org/10.1016/S2213-2600(23)00093-0
  8. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014;189:576-85. DOI: https://doi.org/10.1164/rccm.201309-1575OC
  9. Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy 2021;122:474-88. DOI: https://doi.org/10.4149/BLL_2021_078
  10. Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int J Mol Sci 2022;23:3636. DOI: https://doi.org/10.3390/ijms23073636
  11. Lan CC, Su WL, Yang MC, et al. Predictive role of neutrophil-percentage-to-albumin, neutrophil-to-lymphocyte and eosinophil-to-lymphocyte ratios for mortality in patients with COPD: Evidence from NHANES 2011-2018. Respirology 2023;28:1136-46. DOI: https://doi.org/10.1111/resp.14589
  12. Shojaan H, Kalami N, Ghasempour Alamdari M, et al. Diagnostic value of the neutrophil lymphocyte ratio in discrimination between tuberculosis and bacterial community acquired pneumonia: a meta-analysis. J Clin Tuberc Other Mycobact Dis 2023;33:100395. DOI: https://doi.org/10.1016/j.jctube.2023.100395
  13. Yin Y, Wang J, Wang X, et al. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: a meta-analysis. Clinics 2015;70:524-30. DOI: https://doi.org/10.6061/clinics/2015(07)10
  14. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60:2101499. DOI: https://doi.org/10.1183/13993003.01499-2021
  15. Cheng WC, Chang CL, Sheu CC, et al. Correlating Reiff scores with clinical, functional, and prognostic factors: characterizing noncystic fibrosis bronchiectasis severity: validation from a nationwide multicenter study in Taiwan. Eur J Med Res 2024;29:286. DOI: https://doi.org/10.1183/13993003.congress-2024.PA5111
  16. Man MA, Davidescu L, Motoc NS, et al. Diagnostic value of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in various respiratory diseases: a retrospective analysis. Diagnostics 2021;12:81. DOI: https://doi.org/10.3390/diagnostics12010081
  17. Georgakopoulou VE, Trakas N, Damaskos C, et al. Neutrophils to lymphocyte ratio as a biomarker in bronchiectasis exacerbation: a retrospective study. Cureus 2020;12:e9728. DOI: https://doi.org/10.7759/cureus.9728
  18. Gao Z, Feng Y, Xu J, Liang J. T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy. Front Immunol 2022;13:977394. DOI: https://doi.org/10.3389/fimmu.2022.977394
  19. Coban H, Gungen AC. Is there a correlation between new scoring systems and systemic inflammation in stable bronchiectasis? Can Respir J 2017;2017:9874068. DOI: https://doi.org/10.1155/2017/9874068
  20. Kwok WC, Ho JCM, Lam DCL, et al. Baseline neutrophil-to-lymphocyte ratio as a predictor of response to hospitalized bronchiectasis exacerbation risks. Eur Clin Respir J 2024;11:2372901. DOI: https://doi.org/10.1080/20018525.2024.2372901
  21. Martinez-García MÁ, Olveira C, Girón R, et al. Peripheral Neutrophil-to-Lymphocyte Ratio in Bronchiectasis: A Marker of Disease Severity. Biomolecules 2022;12:1399. DOI: https://doi.org/10.3390/biom12101399
  22. Ghosh P, Gerhardson I, Dahlen B, Bossios A. Neutrophil-to-lymphocyte ratio in patients with bronchiectasis and its correlation with low-grade inflammation; preliminary results from a single tertiary center. Eur Respir J 2020;56:2049. DOI: https://doi.org/10.1183/13993003.congress-2020.2049
  23. Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respir Res 2018;5:e000348. DOI: https://doi.org/10.1136/bmjresp-2018-000348

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.